Transcriptomic profiling of primary human dermal fibroblasts treated with BoNTA
This study aimed to explore the transcriptomic changes in primary human dermal fibroblasts upon treatment with Botulinum toxin type A (BoNTA). BoNTA is a neurotoxin known for its clinical use in dermatology, and emerging evidence suggests potential antifibrotic and anti-inflammatory effects at the cellular level. We performed high-throughput RNA sequencing to assess the global gene expression profiles in fibroblasts treated with BoNTA (1 U/ml) for 24 hours, compared with vehicle control (PBS). This dataset provides valuable insights into the molecular mechanisms of BoNTA in skin-resident fibroblasts and offers a reference for future investigations into its therapeutic roles in fibrotic skin diseases. Overall design: Total RNA was extracted from primary human dermal fibroblasts treated with BoNTA (1 U/ml, n = 3) and from control fibroblasts treated with an equivalent volume of PBS (n = 3). RNA-seq libraries were prepared and sequenced using the Illumina platform. Differential gene expression analysis was performed to identify transcriptional changes induced by BoNTA treatment. All samples were collected after 24 hours of treatment.